| | | | | By Jeff Brown, Editor, The Bleeding Edge | | |
I've been tracking the development of autonomous vehicle technology since 2011 when I sat in one of the earliest Google prototypes of what has become Waymo. | | I rode in my first Tesla in 2016 and bought (leased) my own Tesla in 2023 with full self-driving so I could test and experience every single release of Tesla's self-driving software. | | I know that might sound crazy, but I'm a technologist, and what Tesla has been building is one of the most advanced and revolutionary forms of artificial intelligence (AI)… how could I not stay on top of this? | | I took a strong and very controversial stance in early 2018 with a bullish take on Tesla… that Tesla was actually an AI company that would outpace its competitors in this space and be the one to spearhead the rise of autonomous ride-hailing services across the country and, eventually, the world. | | And now, we're just a couple of months away from Telsa's robotaxi launch in Austin, Texas. I suspect, given the recent permits, that similar services will be available in California within months of the Austin launch. | | Once the technology "proves" itself to be safe in a robotaxi service, convenient, and reliable, it will be all too easy for everyone else, everywhere else, to follow suit. | | | | | Unsupervised autonomous transportation will result in an entire shift in public transportation. It will draw riders away from public buses, trains, and subways as it will be cheaper, cleaner, and safer. No schedules to contend with other than your own. And it will open up entirely new businesses and job opportunities for managing shared autonomous fleets of Teslas. | | | | This is the inflection point. | | This is more powerful than panicked media narratives, stronger than this short-term tariff-powered volatility, and more than ready to run. | | Elon Musk has the Midas touch when it comes to his business ventures. X, xAI, PayPal, SpaceX… everything he touches seems to turn to gold. | | I've predicted that xAI will become the first company in the world to develop an artificial general intelligence (AGI). And it will accomplish this within 12 months. | And now, Tesla – despite media skepticism and the illusion of Tesla's decline, as we covered in last week's AMA – is on the precipice of completely transforming the public transportation industry. | | Which is why, now, before it takes off, is the time to position ourselves. | | I know there's a lot of negative press and uncertainty driving wave after wave of fear in the market right now. But it won't be like this for long. | | Once the fear and uncertainty die down – and they will die down, as I get into briefly in today's AMA – things will pick up again. And we will be glad we saw this moment of anxiety for what it is: an excellent opportunity to snap up high-quality, high-growth stocks at bargain prices. | | Tesla is a great company. It has an incredible future ahead. And what's more, it isn't the only company that's going to thrive once the robotaxi fleet fills the streets of our cities. | | I've got my eye on a handful of smaller companies connected to the rise of robotaxis… opportunities in quieter corners of the industry that stand to gain so much more once Musk's Cybercabs hit the roads. | | You can learn more about them in my Robotaxi Emergency Briefing next Thursday, April 10, at 1 p.m. ET. | | We'll take some time that afternoon to expand on all I've said here – how this technology has developed and particularly Elon's role in advancing it – and the group of companies I believe stand to gain the most. | | | | Now, on to the AMA… | | The Incredible Future of Agentic AI | | | Hi Jeff, | | Are you and your team working on any new Physical AI, Agentic AI, and AI Super Agents stocks to invest in? Numerous articles are inferring AI is replacing a lot of jobs with these new AI versions. I would be very interested in hearing if this is really going on or just propaganda. | | Thanks, | | – Russ N. | | | | Hi Russ, | | Absolutely, we already have several picks-and-shovels tech companies that are key providers for various forms of Physical AI in the Near Future Report. And in Exponential Tech Investor, there are a few companies that have already begun to use Agentic AI technology in their product offerings. You can access these in your subscriber portal. | | It is definitely not propaganda. This technology is being employed already in both agentic form and physical/manifested forms. | | As I've written previously, the major focus for 2025 in AI software is agentic AI technology. Giving an AI agency empowers it to perform more complex tasks that require reasoning. And that means incredible utility and productivity for us humans. | And if you didn't get a chance to read yesterday's Bleeding Edge – A Step Ahead, I think you'll find this relevant to your question. The last couple of weeks have been really exciting with major improvements in the mobility/locomotion of humanoid forms of Physical AI. | | | | | Agentic AIs can interact with the real world by performing specific tasks without human intervention. | | That means these agentic AIs can perform highly repetitive tasks, freeing up capital and labor for higher use cases. | | They aren't meant to replace the workforce but rather to participate alongside us in the workforce. It's, in part, why PricewaterhouseCoopers estimates agentic AI's impact to be between $2.6 and $4.4 trillion annually to global GDP by 2030. | | It's a goldmine of untapped productivity. This type of future is known as the "Agentic Economy." | | | | Agentic AI is finding early adoption in areas like customer service, insurance, business operations, fraud detection, algorithmic trading, logistics, supply chain management, the blockchain industry, and things like e-discovery. | | There is some job loss already. For example, the insurance industry can use agentic AI for underwriting, and claims processing, dramatically improving efficiency and lowering operational costs. | | But as some jobs are lost, many others will be created, many that never existed before. This is especially true when it comes to Physical AI, which is a greenfield opportunity that will require new infrastructure to be built to support and maintain physical manifestations of intelligent AI. | | My team and I have been ahead of this trend from the very beginning, and it will continue to be a key area of research and investment recommendations for years to come. Your timing is great to be interested in this sector. | | | | In 2011, Silicon Valley insider Jeff Brown rode in an early self-driving car… In 2018, he recommended Tesla… And last year, he blindfolded himself in a Cybertruck to show that Tesla's self-driving technology was ready for prime time. Now the day has come. As early as June 1, Tesla is set to launch its initial fleet of self-driving robotaxis. And for a limited time, you have the chance to get ahead of the small companies set to soar. On Thursday, April 10, at 1 p.m. ET, Jeff's sharing the details in The Robotaxi Emergency Briefing – including the name of one of his top picks completely FREE. Register Here With a Single Click
(When you click the link, your name will automatically be added to Jeff's guest list.) | | | | DC Blockchain Summit 2025 | | | Hello Jeff and Ben, | | Sharing my notes from the DC Blockchain Summit today. I apologize for not getting a chance to formally meet you today. Every time I saw you, you were either listening intently or visiting with other people… so out of respect I did not want to interrupt. | | It was a wild summit environment today but hope to have a deeper discussion with each of you in the future. I have been a member of Jeff's work since the days he launched his options services and have been through the good, the bad, and the ugly. | | I am also thankful he came to an agreement with Marketwise and was honorable to his agreement with his lifetime members. I had shouted from the mountain tops to Mark (CEO at the old Stansberry) about Jeff's intelligence and work. So glad things worked out. You guys are a staple in my knowledge work. | | Hope my notes help supplement any sessions you might have missed today. Always happy to support the greater good of our community. | | – Greg R. | | | | Hi Greg, | | Thanks for your feedback, it means a lot. And I really wish you would have come up and said hello. A few others from the Brownstone community did so at the conference, and it was great to connect. It's always nice to meet subscribers when I'm out traveling. | | It's such an odd environment in the digital assets industry right now. As you heard at the Summit, the atmosphere was ridiculously bullish. The level of alignment between industry, policymakers, politicians, and regulators is extraordinary. I've never seen anything like it. | | And yet… The digital assets industry is getting punished right now. Everything is aligned for what should be the beginning of a major bull market but is extremely "risk off" right now. It's always painful to see this happen, even more so when we know that things will eventually run… | | What we do know however is that the fear and uncertainty over the tariffs & tariff negotiations will lessen quickly once we get through the next two or three weeks. After this week's pain, asset prices in the equity markets are presenting some incredible investment opportunities. Many valuations are downright cheap right now. | | And more relevant to the digital asset space, so much progress is being made on the regulatory front between stablecoins (with legislation coming this month) to market structure (with legislation ready by June) that it's hard not to be bullish. | | And all the malicious and politically driven lawsuits have been summarily dropped by the SEC now that new leaders are at the helm. Regulatory clarity, even if in draft forms, will allow the industry to move forward, continue to invest, and ultimately create a lot of value and wealth. | | Thanks for being so thoughtful to send in your notes from the conference as well. With so much going on and all the sidebar sessions (typically standing room only), it was impossible to catch everything. | | We'll see you next time… | | What Does the Future of Cancer Treatment Look Like? | | | Hi Jeff and Team, | | I just watched an amazing interview with Tucker Carlson and Dr. Patrick Soon-Shiong. It interested me both medically and with investments in mind. They go over how cancer treatment has been wrong for 50 years, problems with the FDA, and how they treat innovators compared to Big Pharma etc. There is a lot of science talked about in the interview and very interesting. | | I am a physician and have been very skeptical about the Covid vaccine but still trust normal vaccines. I am sharing the interview here and how your team has time to review it. If Dr. Soon-Shiong is right, and I think he very well may be, there is a lot of potential in the area of immunology innovation and cancer treatment. Hope you all get a chance to review this and give us all some thoughts. | | – Daniel K. | | | | Hello Daniel, | Thanks for writing in about such an interesting topic. There were some very interesting aspects of the interview which are worth discussing. For readers who are interested in watching the interview, you can access it on YouTube right here. | | There is also a lot of context that wasn't discussed at all in the interview that is highly relevant and important to understand concerning Dr. Soon-Shiong. We'll get to that. | | Soon-Shiong's criticisms of the way that cancer has been and still is being treated are very fair. There continues to be a lot of research and development working on therapeutic approaches to cancer that are more targeted, personalized, and have fewer side effects than the current standard of care. | Soon-Shiong's company ImmunityBio (IBRX) is one of those companies. It's the entity within which the BioShield product that he mentioned so many times in the interview is being developed. | | I appreciated his comments about the deep state and how parts of the NIH, CDC, and FDA have been involved in stifling innovation and even suppressing effective therapies that could solve major health problems. We certainly experienced that firsthand during the COVID-19 pandemic. | | All it takes to understand why the NIH and so many government officials lied to the world about the safety and efficacy of the COVID-19 "vaccines" is to follow the money. | | Between 2022 and 2023, pharmaceutical companies paid the NIH, its leadership, and scientists more than $710 million in third-party royalties. The way this happened is the pharmaceutical companies structured the payments as royalties for "licensed inventions" created by government employees in taxpayer-funded labs. | | | | Source: Openthebooks.com | | Almost no one understands the perverse incentives created when government employees can become multimillionaires if they support, push, and recommend an experimental drug for which they are named in a "licensed invention." | | Of the $710 million, $690 million went to Dr. Fauci's National Institute of Allergies and Infectious Diseases (NIAID). | | To put things in context, the average amount of royalties that NIAID received in prior years was around $2 million a year. Absolutely extraordinary. And an unbelievable conflict of interest. To avoid this conflict, the solution is simple. Taxpayer-funded employees of the government should not be eligible to receive any royalties from biopharmaceutical companies. | | I'm 100% with you on the COVID-19 "vaccine." Actually, it's not a vaccine. It's an experimental drug that has proven to be ineffective and unsafe. | - It does not stop infection
- It does not stop the replication of the virus
- It does not stop the transmission of the virus
| | What it does is make billionaires in the private sector and multimillionaires in the government. | | I was disappointed that Soon-Shiong was not more forthcoming with the known dangers and side effects of the COVID-19 "vaccine." | | He slipped up one time in the interview when he said something along the lines of, "I don't know why we keep giving this nonsense" when referring to injecting people with the COVID-19 "vaccines." He then quickly paused and said, "I should be careful." After all, he is a biotech executive trying to get his drugs approved by the FDA. | | He refused during the interview to discuss the extensive research regarding COVID-19 vaccine injury. | | The closest he got was when he said, "Sometimes the virus is the cause, and sometimes the vaccine is the cause," when referring to those who have had health problems related to COVID-19 or the mRNA shots. | | This is so disappointing, but again, he fears the deep state and claims that he and his business have been directly impacted by the deep state, so he was being very careful. | | Just a couple of months ago, Yale published some research that clearly linked the risk of death, deadly disease, and disability caused by the mRNA COVID-19 "vaccines." This is from Yale, one of the staunch supporters of the COVID-19 mRNA shots, heavy masking, social distancing, and a "pandemic of the unvaccinated" rhetoric. | | | | The findings of the research prove that those "vaccinated" with the mRNA drugs face dangerous side effects for years after the last injection. The researchers are calling this condition "post-vaccination syndrome" (PVS). | | They even went so far as to suggest that PVS resembles what most refer to as "long COVID." I have long stated that, except for a diminished sense of taste or smell, long COVID is, in fact, vaccine injury. | | Another bombshell report that analyzed 99 million vaccinated individuals resulted in the following findings for those who took the mRNA shots… | - 610% increased risk of myocarditis
- 378% increased risk of acute disseminated encephalomyelitis
- 323% increased risk of cerebral venous sinus thrombosis
- 249% increased risk of Guillain-Barre syndrome
| | | | Please keep in mind that these are not easy to read, and you have to look at the data tables to calculate the increased risk percentages for these diseases caused by the mRNA shots. | | This is all very relevant to the discussion with Soon-Shiong as the mRNA shots are also linked to the production of a protein called IgG4. | | When the body produces an abundance of IgG4, it acts as a suppressant to the body's natural immune system. This is what is believed to be the key mechanism for the wave of "turbo cancers" that suddenly began in the spring of 2021 immediately after the mRNA shots began. The presence of IgG4 and its impact on our immune system gives cancer cells free rein to thrive and multiply in our bodies. | | Soon-Shiong referred to these turbo cancers but was very careful to avoid controversy by linking them to the mRNA shots, despite there being a wide range of peer-reviewed scientific research that has already done so. | | Daniel, I agree with you about some vaccines – actual vaccines, like those for polio and tuberculosis. When an inactive or attenuated virus is used as a vaccine, the body is exposed to the whole virus and can build natural immunity to that virus. | | But the flu "vaccine" and the COVID "vaccine" are not vaccines. And more children die in the U.S. from the MMR vaccine for measles than they do from measles itself. I have to say that I agree with RFK Jr. that we need to be evidence-based, review the entire vaccine schedule, and determine what is safe and effective. | | And RFK Jr. also did something smart by announcing his plan to create a research group to study vaccine injuries. | | He made it generic to avoid an uproar, which was smart. But this research needs to be done. It needs to be backed by data. And those who have been harmed by the mRNA shots, or any other "vaccine," need to be cared for and, preferably, funded by the pharmaceutical companies that caused the damage (i.e. not by taxpayers). | | Also worth mentioning is that seven U.S. states have already introduced legislation to ban the mRNA COVID-19 "vaccines." | | While the media doesn't cover these developments, all of the vaccine injuries and related deaths have been widely discussed in congressional hearings which have all been a matter of public record. I stand by my prediction that these shots will be pulled from the market before the end of this year. | | One final point about Soon-Shiong. | | He is a controversial figure in the industry and has been known to make aggressive claims about his own products from which he stands to benefit financially. He "pumped" BioShield throughout his interview with Tucker. It sounded great, didn't it? The cure for cancer? | | But much of the data hasn't been published to back up his claims. | | The share price of his company, ImmunityBio, has been languishing for years. An argument can be made for his intentional efforts to generate excitement in BioShield. | Perhaps not coincidentally, ImmunityBio is now hosting an Investor Day on April 15 to share the latest developments on BioShield and what ImmunityBio has been developing. For anyone curious, you can listen in… | | With that said, I sincerely hope that Soon-Shiong and his team are successful with their therapeutic developments for cancer, and, if they work, I hope they get FDA approvals. | | Cancer therapies are in long need of a major upgrade as I myself have discovered in going to the bleeding edge of modern medicine to cure my own cancer. I have found it impossible to get support from traditional oncologists or urologists for therapeutic approaches outside of the standard approach as approved by their medical boards. | | I've learned a tremendous amount in the process and believe I've figured out how to cure myself outside of the system. | | The time has come, | | Jeff | | | | | | | A humanoid robot's gait or motion is slower than a human's. While capable of performing tasks with precision around... | | | | | | Over the past few years, Intel has been like a slow-motion train wreck, one bad decision after another. But... | | | | | | There's no turning back now. We can expect at least one major announcement concerning a frontier AI reasoning model... | | | | | | | | | | | | | | | To ensure our emails continue reaching your inbox, please add our email address to your address book. This editorial email containing advertisements was sent to ahmedwithnour@gmail.com because you subscribed to this service. To stop receiving these emails, click here. Brownstone Research welcomes your feedback and questions. But please note: The law prohibits us from giving personalized advice. To contact Customer Service, call toll free Domestic/International: 1-888-512-0726, Mon-Fri, 9am-7pm ET, or email us here. © 2025 Brownstone Research. All rights reserved. Any reproduction, copying, or redistribution of our content, in whole or in part, is prohibited without written permission from Brownstone Research. | | | | |
